Question explored with the scientific record
Why take a covid vax in 2026?
The honest answer for 2026: the evidence for a mortality benefit is real but conflicted, and the case is strongest for older and frail adults, weakest for healthy young people.
The best evidence for a benefit is observational, not randomized. A Norwegian cohort of 4.6 million adults found fully vaccinated people (three or more mRNA doses) died at roughly 40% the rate of unvaccinated people across all three age bands, adjusted for sex, county, time, and risk group [4]. A Hungarian nationwide cohort found the same direction after correcting for the healthy-vaccinee effect, with effectiveness against all-cause death ranging from about 49% to 75% depending on the vaccine [5]. Both are cohort studies, so residual confounding is possible, and the authors say so [4][5].
The counter-evidence is also real and points the other way. English and UK data show early protection that later reversed, with non-COVID mortality staying relatively high among the vaccinated as it fell among the unvaccinated [1][3]. A US county-level study found higher vaccine uptake tracked with higher 2022 and 2023 excess mortality, though it cannot prove cause [2]. A Japanese analysis found lower mortality in highly vaccinated 65-89 year olds but higher mortality in younger adults with five or more doses [6]. These are ecological and observational designs, and they conflict with the cohorts above.
| Finding | Direction | Design |
|---|---|---|
| Norway, 4.6M adults | ~40% lower death rate, vaccinated | Cohort [4] |
| Hungary, 6.4M adults | 49-75% lower, HVE-corrected | Cohort [5] |
| England, 2021-23 | Later non-COVID mortality higher in vaccinated | Ecological [1] |
| US counties, 2022-23 | Higher uptake, higher excess mortality | Ecological [2] |
| Japan, 20-49 with 5+ doses | Higher mortality | Exploratory [6] |
What this retrieval does not contain: any randomized trial of the current 2026 formula against a true placebo with all-cause mortality as the endpoint. That is the study that would settle it, and it is not here. The evidence base is observational and conflicted, and the manufacturer-funded trials that do exist used short-term symptomatic infection as the endpoint, not death [7][8].
My call: for a healthy adult under 50 with prior infection, the marginal benefit is small and the long-term safety data is thin; for an older or frail adult, the observational signal favors vaccination, with moderate confidence. Confidence: moderate for older adults, low for healthy young adults.
Sources used 8
-
The temporal protection and declining health of the COVID-19 vaccinated in England: A 26-month comparison of the mortality involving and not involving COVID-19 among vaccinated vs. unvaccinated
Using English monthly age-standardized mortality data from Apr 2021 to May 2023, the study finds that unvaccinated individuals had initially higher all-cause and non-COVID mortality, that vaccinated individuals showed temporary protection between Jul 2021 and Jan 2022, and that …
DOI: 10.12688/f1000research.160980.1 -
Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people
A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.
DOI: 10.12688/f1000research.177279.1 -
All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data
The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…
DOI: 10.12688/f1000research.154058.2 -
COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study
In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…
DOI: 10.1136/bmjph-2024-001859 -
Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study
In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…
DOI: 10.3390/vaccines10071009 -
Age-specific patterns of all-cause mortality across COVID-19 booster dose groups in two Japanese municipalities: an exploratory analysis
Exploratory analysis of Japanese municipal registry data found lower all-cause mortality among highly vaccinated adults aged 65-89 years but higher all-cause mortality among adults aged 20-49 years with ≥5 doses and those aged 50-64 with six doses, with causality unestablished.
DOI: 10.3389/fpubh.2026.1795437 -
VACCIN COMIRNATY CONTRE LA COVID-19 : UNE AIDE A LA DECISION
This advisory from the scientific council of CNGE summarizes the Pfizer-BioNTech Comirnaty COVID-19 vaccine trial, reporting 95% relative risk reduction for symptomatic COVID-19, describes common side effects, and notes missing data on older adults, hospitalizations, mortality, …
DOI: 10.56746/exercer.2021.169.23 -
Vaccin Moderna mRNA-1273 contre la Covid-19 : une aide à la décision
This commentary summarizes the phase 3 mRNA-1273 trial results and presents decision aids for Moderna vaccination, noting that efficacy in adults 75+ was not conclusive.
DOI: 10.56746/exercer.2021.175.320